UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia

First California institution selected to participate in GSK’s bench-to-bedside academia-industry collaboration program —

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team. … Read the full story from the UC San Diego Newsroom

Division of Regenerative Medicine Holds First Research Symposium

Catriona H. M. Jamieson, MD, PhD

Dr. Catriona Jamieson

On Friday, January 30, the Division of Regenerative Medicine presented its inaugural symposium on novel research and technologies in regenerative medicine.

The meeting featured scientific presentations by world-renowned academic investigators and industry leaders as well as a discussion panel including keynote speakers Dr. Hans Clevers, Dr. Derrick Rossi, Dr. Carl June and Dr. Wolfgang Dillmann.

Division Chief Catriona Jamieson, MD, PhD, presented the mission and milestones of the new Division of Regenerative Medicine after introductions from UC San Diego Chancellor Pradeep Khosla; Vice Chancellor Health Sciences and Dean of UC San Diego School of Medicine Dr. David Brenner; and Chief Executive Officer of UC San Diego Health System and Associate Vice Chancellor of UC San Diego Health Sciences Paul Viviano.

UC San Diego Moores Cancer Center

UC San Diego Moores Cancer Center

Catriona Jamieson, MD, PhD, is associate professor in the Division of Hematology-Oncology, deputy director of the Sanford Stem Cell Clinical Center, chief of the Division of Regenerative Medicine and director of stem cell research at the Moores Cancer Center.

Novel Drug Targeting Leukemia Cells Enters Clinical Trial

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. … Read the full story from the UC San Diego Newsroom


A team led by Dr. Thomas Kipps developed the new antibody, known as cirmtuzumab or UC-961. The work was conducted and supported by a California Institute for Regenerative Medicine HALT grant to co-principal investigators Dennis Carson, MD, and Catriona Jamieson, PhD, MD.

Dr. Thomas Kipps

Catriona H. M. Jamieson, MD, PhDDennis Carson, MD

L to R: Drs. Kipps, Jamieson and Carson.

Researchers Block Pathway to Cancer Stem Cell Self-Renewal

NOTCH1 Signaling Promotes T-Cell Acute Lymphoblastic Leukemia-Initiating Cell Regeneration

Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells … A team of researchers – led by Catriona H. M. Jamieson, MD, PhD, associate professor of medicine at the University of California, San Diego School of Medicine and director of Stem Cell Research at UC San Diego Moores Cancer Center – studied these cells in mouse models that had been transplanted with human leukemia cells. They discovered … Read the full story from the UCSD Newsroom


Dr. Catriona JamiesonThe senior investigator of the study described in the press release is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

In the study, the investigators successfully block leukemia stem cell self-renewal. Their work was funded in part by a California Institute for Regenerative Medicine (CIRM) Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) Leukemia Disease Team Research grant for which Dr. Jamieson serves as co-principal investigator with Dennis A. Carson, MD, former director of the Moores Cancer Center.

The overall goal of the HALT project is to develop six drugs – three monoclonal antibodies and three small molecules – to destroy leukemia stem cells.

Funding also came from the Ratner Family Foundation and the Leichtag Family Foundation. Antibody development was performed by Pfizer.

In her research, Dr. Jamieson focuses on translational studies to develop new treatments for myeloproliferative disorders and leukemia. In 2010, she received a $3.34 million grant from CIRM to support her efforts to develop treatments that reduce the risk of relapse in leukemia.  More about this funded project

Dr. Jamieson was named to the “San Diego’s Top Doctors” list for 2010 and 2011.

More information:

Dr. Catriona Jamieson Receives $3.34 Million CIRM Grant for Leukemia Research

Dr. Catriona Jamieson

Dr. Catriona Jamieson has received a $3.34-million Early Translational II award from the California Institute for Regenerative Medicine (CIRM).

Dr. Jamieson, Assistant Professor of Medicine in the Division of Hematology-Oncology, is Director of Stem Cell Research at the Moores UCSD Cancer Center. The new CIRM award will support her efforts to develop treatments that reduce the risk of relapse in leukemia.

Dr. Jamieson is one of two UCSD researchers to receive CIRM grants this week.

Read the full story from the UCSD Newsroom.

Read a 2008 interview with Dr. Jamieson about her leukemia research.

In the Media: Dr. Catriona Jamieson

Dr. Catriona Jamieson is one of the researchers interviewed in the CBS Evening News story, “Where America Stands: Stem Cell Research.” The story highlights Dr. Jamieson’s studies of cancer stem cells, their role in the development and recurrence of cancer, and the investigational new drug that targets a cancer stem cell type associated with a form of leukemia.

Dr. Jamieson’s research is also featured in two stories in The Huffington Post:

Catriona Jamieson, M.D., Ph.D., is Assistant Professor of Medicine in the Division of Hematology-Oncology and Director of Stem Cell Research at the Moores UCSD Cancer Center.

Also interviewed in the CBS Evening News story is UCSD’s Dr. Larry Goldstein, Professor in the Department of Cellular and Molecular Medicine and Director of the UC San Diego Stem Cell Program.

Translational Stem-Cell Research: Potential New Treatment for Blood Disorders Now in Clinical Trial

Dr. Catriona M. H. Jamieson and colleagues are performing the first clinical trial of a promising new treatment that was identified in the laboratory only last year.

The treatment may offer new hope to individuals who have myeloproliferative disorders (MPDs). MPDs can evolve into leukemia.

Catriona M. H. Jamieson, M.D., Ph.D., is Director for Stem Cell Research at the Moores UCSD Cancer Center. She is Assistant Professor of Medicine in the Division of Hematology-Oncology.

The findings that led to the clinical trial were published in Cancer Cell in April 2008. Read the report

Read the full story from UC San Diego Health Sciences Communications

More Information: